Insmed Incorporated (INSM) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $97.85: Leverage penalty (D/E 1.1): -0.5; Concentration risk — Product: ARIKAYCE and BRINSUPRI.
Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE (amikacin liposome inhalation suspension) approved for refractory MAC lung disease in the US, EU, and Japan, and BRINSUPRI (brensocatib) approved for non-cystic fibrosis bronchiectasis in the US... Read more
Sell if holding. Multiple concerning factors at $97.85: Leverage penalty (D/E 1.1): -0.5; Concentration risk — Product: ARIKAYCE and BRINSUPRI. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Insmed Incorporated
Latest news
- NEWS Analysts’ Opinions Are Mixed on These Healthcare Stocks: United Therapeutics (UTHR), Insmed (INSM) and MannKind (MNKD) - — The Globe and Mail neutral
- NEWS Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis - PR Newswire — PR Newswire positive
- NEWS Insmed (INSM) CEO sells 10,699 shares and exercises options under 10b5-1 plan - Stock Titan — Stock Titan negative
- NEWS INSM (Insmed Incorporated) Q4 2025 EPS misses consensus estimates, shares rise 5.07 percent on positive investor sentime — Newser negative
- NEWS What Insmed Incorporated (INSM) does that keeps customers coming back (-0.41%) 2026-05-05 - Insider Selling - Newser — Newser negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductARIKAYCE and BRINSUPRI10-K Item 1A: 'Our prospects are highly dependent on the success of our approved products, ARIKAYCE and BRINSUPRI'
Material Events(8-K, last 90d)
- 2026-02-19Item 5.02LOWDavid W.J. McGirr, board member and Audit Committee chair, notified the board on February 17, 2026 that he will not stand for re-election at the 2026 Annual Meeting. Will serve until the meeting. Decision not a result of any disagreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $97.85: Leverage penalty (D/E 1.1): -0.5; Concentration risk — Product: ARIKAYCE and BRINSUPRI. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $91.00. Score 5.6/10, moderate confidence.
Take-profit target: $177.86 (+81.8% upside). Prior stop was $91.00. Stop-loss: $91.00.
Concentration risk — Product: ARIKAYCE and BRINSUPRI; Leverage penalty (D/E 1.1): -0.5; Consecutive earnings misses (3).
Insmed Incorporated trades at a P/E of N/A (forward 301.3). TrendMatrix value score: 3.8/10. Verdict: Sell.
29 analysts cover INSM with a consensus score of 4.3/5. Average price target: $198.
What does Insmed Incorporated do?Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE (amikacin liposome inhalation...
Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE (amikacin liposome inhalation suspension) approved for refractory MAC lung disease in the US, EU, and Japan, and BRINSUPRI (brensocatib) approved for non-cystic fibrosis bronchiectasis in the US (August 2025) and EU (November 2025). The pipeline includes TPIP (PH-ILD/PAH) in Phase 3 and gene therapy programs for DMD and ALS. The company has no history of profitability.